These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

501 related articles for article (PubMed ID: 9101397)

  • 1. Prevention and slowing down the progression of the diabetic nephropathy through antihypertensive therapy.
    Bretzel RG
    J Diabetes Complications; 1997; 11(2):112-22. PubMed ID: 9101397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of antihypertensive drugs on renal function in patients with diabetic nephropathy.
    Bretzel RG
    Am J Hypertens; 1997 Sep; 10(9 Pt 2):208S-217S. PubMed ID: 9324124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can we further slow down the progression to end-stage renal disease in diabetic hypertensive patients?
    Bretzel RG
    J Hypertens Suppl; 1997 Mar; 15(2):S83-8. PubMed ID: 9218204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal protection and antihypertensive drugs: current status.
    Salvetti A; Mattei P; Sudano I
    Drugs; 1999 May; 57(5):665-93. PubMed ID: 10353294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protecting the residual renal function: which drugs of choice?
    Bretzel RG
    Am J Hypertens; 1997 Jul; 10(7 Pt 2):159S-166S. PubMed ID: 9231893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolving strategies for renoprotection: diabetic nephropathy.
    Parving HH; Hovind P; Rossing K; Andersen S
    Curr Opin Nephrol Hypertens; 2001 Jul; 10(4):515-22. PubMed ID: 11458033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Risk and prevention of diabetic nephropathy].
    Ravera M; Re M; Deferrari G
    G Ital Nefrol; 2007; 24 Suppl 38():13-9. PubMed ID: 17922442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is antihypertensive treatment the same for NIDDM and IDDM patients?
    Parving HH
    Diabetes Res Clin Pract; 1998 Apr; 39 Suppl():S43-7. PubMed ID: 9649959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidence.
    Ruilope LM; Segura J
    Clin Ther; 2003 Dec; 25(12):3044-64. PubMed ID: 14749145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
    Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of angiotensin II antagonism in type 2 diabetes mellitus: a review of renoprotection studies.
    Zanella MT; Ribeiro AB
    Clin Ther; 2002 Jul; 24(7):1019-34. PubMed ID: 12182249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of antihypertensive agents in prevention and treatment of diabetic nephropathy.
    Parving HH; Rossing P
    Curr Opin Nephrol Hypertens; 1994 May; 3(3):292-300. PubMed ID: 7922255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microalbuminuria in type 1 and type 2 diabetes mellitus: evidence with angiotensin converting enzyme inhibitors and angiotensin II receptor blockers for treating early and preventing clinical nephropathy.
    Parving HH; Hovind P
    Curr Hypertens Rep; 2002 Oct; 4(5):387-93. PubMed ID: 12217258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Losartan in diabetic nephropathy.
    Perico N; Ruggenenti P; Remuzzi G
    Expert Rev Cardiovasc Ther; 2004 Jul; 2(4):473-83. PubMed ID: 15225108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of diabetic nephropathy with angiotensin II receptor antagonist.
    Lewis EJ; Lewis JB
    Clin Exp Nephrol; 2003 Mar; 7(1):1-8. PubMed ID: 14586737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Micro-albuminuria and the organ-damage concept in antihypertensive therapy for patients with insulin-dependent diabetes mellitus.
    Mogensen CE; Petersen MM; Hansen KW; Christensen CK
    J Hypertens Suppl; 1992 Apr; 10(1):S43-51. PubMed ID: 1619502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
    Vogt L; Kocks MJ; Laverman GD; Navis G
    Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural history of early diabetic nephropathy: what are the effects of therapeutic intervention? Melbourne Diabetic Nephropathy Study Group.
    Jerums G; Allen TJ; Gilbert RE; Hammond J; Cooper ME; Campbell DJ; Raffaele J
    J Diabetes Complications; 1995; 9(4):308-14. PubMed ID: 8573754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Slowing the progression of chronic renal insufficiency with captopril in rats with spontaneous arterial hypertension and adriamycin nephropathy].
    Jovanović DB; Jovović Dj; Varagić J; Dimitrijević J; Dragojlović Z; Djukanović L
    Srp Arh Celok Lek; 2002; 130(3-4):73-80. PubMed ID: 12154518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in the treatment of diabetic renal disease: focus on losartan.
    Rayner B
    Curr Med Res Opin; 2004 Mar; 20(3):333-40. PubMed ID: 15025842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.